无创检查动态变化在指导丙型肝炎治愈后肝硬化患者肝细胞癌监测决策中的价值
本研究基于法国两个前瞻性多中心队列(ANRS CO22 Hepather 和 CO12 CirVir)2006至2015年间纳入的3067例获得持续病毒学应答的肝硬化患者,描述无创检查(FIB-4、APRI、肝脏硬度值)的动态变化,并采用联合模型评估其与肝细胞癌风险的相关性。结果显示,未发生肝细胞癌的患者所有无创检查均改善,而发生肝细胞癌的患者变化更多样;无创检查的当前值比斜率更具信息价值。结论认为,无创检查的动态变化不能识别可安全排除于监测程序之外的肝硬化患者。
要点
- 在获得持续病毒学应答的肝硬化患者中,未发生肝细胞癌者所有无创检查均改善,而发生肝细胞癌者变化更多样。
- 联合模型分析显示,FIB-4、APRI和血小板计数的当前值在任何时间点均影响肝细胞癌风险,仅FIB-4和APRI的斜率影响该结局。
- 同时考虑当前值和斜率时,仅无创检查的当前值影响肝细胞癌风险,斜率不提供额外信息。
核心结论
- 持续病毒学应答后无创检查的动态变化不能识别可安全排除于监测程序之外的肝硬化患者。
- 无创检查的当前值比斜率更具信息价值,需要定期重新评估肝细胞癌风险以设计个体化监测策略。
- 在丙型肝炎病毒清除后,所有肝硬化患者均应维持肝细胞癌监测,即使无创检查值下降。
研究设计与样本
- 研究纳入法国两个前瞻性多中心队列(ANRS CO22 Hepather 和 CO12 CirVir)2006至2015年间获得持续病毒学应答的肝硬化患者。
- 共分析3067例获得持续病毒学应答的肝硬化患者,其中228例(7.4%)发生肝细胞癌,210例(6.9%)在26个月随访期间死亡。
- 采用联合模型方法,使用标准和灵活模型并校正年龄和性别,评估无创检查当前值和随访期间斜率对肝细胞癌风险的影响,并考虑死亡竞争风险。
主要发现
- 最终发生肝细胞癌的患者基线时所有无创检查均升高,而血小板计数较低。
- 未发生肝细胞癌的患者所有无创检查均改善;最终发生肝细胞癌的患者随访期间变化更多样。
- 联合模型分析显示,FIB-4、APRI和血小板计数在任何时间点的当前值均影响肝细胞癌风险。
- 仅FIB-4和APRI的斜率影响肝细胞癌风险。
- 同时考虑无创检查当前值和斜率时,仅当前值影响肝细胞癌风险,斜率不提供信息。
临床怎么用
- 在丙型肝炎病毒清除后,所有肝硬化患者均应维持肝细胞癌监测,即使无创检查值下降。
- 无创检查当前值比斜率更具信息价值,需要定期重新评估肝细胞癌风险以设计个体化监测策略。
- 作者认为,需要专门的前瞻性研究来定义如何将无创检查的重复测量与其他变量结合到肝细胞癌风险分层算法中。
局限性
- 作者指出,需要专门的前瞻性研究来定义如何将无创检查的重复测量与其他变量结合到肝细胞癌风险分层算法中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Whether the dynamics of non-invasive tests (NITs) correlate with hepatocellular carcinoma (HCC) risk in patients with cirrhosis following sustained virological response (SVR) remains unknown. Thus, we aimed to describe NIT dynamics and assess their correlation with HCC risk. METHODS: The dynamics of NITs (fibrosis-4 index [FIB-4], aspartate aminotransferase-to-platelet ratio index [APRI] and liver stiffness measurement) were described in patients with cirrhosis after SVR included in two prospective French multicenter cohorts (ANRS CO22 Hepather and CO12 CirVir) between 2006 and 2015. To assess their relationship with the risk of HCC, a joint modeling approach was employed using both standard and flexible models adjusted for age and sex. The impacts of NIT current value and slope during follow-up on HCC risk were assessed, considering competing risks of death. RESULTS: A total of 3,067 patients with cirrhosis who achieved SVR were analyzed, among whom 228 (7.4%) developed HCC and 210 (6.9%) died during a 26-month follow-up. All NITs were increased at baseline in patients who ultimately developed HCC, whereas platelet counts were lower. All NITs improved in patients who did not develop HCC. More varied changes were observed during the follow-up of patients who ultimately developed HCC. Joint model analyses showed that current values of FIB-4, APRI and platelet count at any time impacted HCC risk. Only FIB-4 and APRI slopes influenced the same outcome. When considering NIT current value and slope simultaneously, only the current value of NITs impacted HCC risk while the slopes were not informative. CONCLUSIONS: The dynamics of NITs following SVR do not identify patients with cirrhosis who could be safely excluded from surveillance programs. NIT current value is more informative than slope, which will necessitate regularly re-assessment of HCC risk to design individualized surveillance strategies. IMPACT AND IMPLICATIONS: It has been postulated that monitoring non-invasive test (NIT) dynamics following HCV cure may provide information on the residual risk of hepatocellular carcinoma (HCC) in patients with cirrhosis and may allow for the discontinuation of surveillance in certain patient subsets. We analyzed data from over 3,000 patients and found that while all NITs improved in patients with cirrhosis who did not develop HCC, those who eventually developed liver cancer showed more varied changes in these tests. Specifically, the current values of tests like FIB-4 (fibrosis-4 index) and APRI (aspartate aminotransferase-to-platelet ratio index) were linked to an increased risk of HCC, while their slopes did not provide additional useful information, suggesting that dedicated prospective studies are warranted to define how repeated measurement of NITs could be combined with other variables into HCC risk stratification algorithms. Until then, HCC surveillance should be maintained in all patients with cirrhosis following HCV eradication, even in case of decreased NIT values.
引用
- Nahon P, Lusivika-Nzinga C, Merle P, et al. Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis. J Hepatol. 2025. PMID: 40020929. doi:10.1016/j.jhep.2025.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。